Sector News

Novartis and Pfizer link to develop NASH combo therapy

October 29, 2018
Life sciences

Novartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease.

The clinical development pact will include a study combining Novartis’ Farnesoid X receptor agonist tropifexor with one or more Pfizer compounds for the treatment of NASH, including an acetyl CoA-carboxylase inhibitor (PF-05221304), a diacylglycerol O-acyltransferase 2 inhibitor (PF-06865571), and a ketohexokinase inhibitor (PF-06835919).

There are currently no options available to treat NASH, which the firms note presents “a high unmet patient need” as it affects up to 6.5% of the population worldwide and is largely asymptomatic.

As fat builds up in the liver, it can trigger a cycle of chronic inflammation and liver scarring (fibrosis) which, over time, can cause cirrhosis, liver failure and death.

“Liver diseases, including NASH, are multifaceted with various factors that contribute to the progression of the disease. This makes them difficult to treat with a single compound,” said Eric Hughes, Global Development Unit head, Immunology, Hepatology and Dermatology.

“We want to collaborate with multiple partners to drive the science and understanding of how to treat non-viral liver diseases. Targeting different pathways in NASH with a broad array of therapies is an essential strategy to bring the best treatments to patients.”

Further details and of the deal were not disclosed.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.